샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793016

세계의 맨틀세포 림프종 시장

Mantle Cell Lymphoma
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 369 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

맨틀세포 림프종 세계 시장은 2030년까지 37억 달러에 달할 전망

2024년에 25억 달러로 추정되는 맨틀세포 림프종 세계 시장은 분석 기간인 2024-2030년에 CAGR 6.8%로 성장하여 2030년에는 37억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 임상 검사 진단은 CAGR 8.3%를 기록하며 분석 기간 종료시에는 19억 달러에 달할 것으로 예측됩니다. 영상 검사 진단 부문의 성장률은 분석 기간 동안 CAGR 5.0%로 추정됩니다.

미국 시장은 6억 6,870만 달러로 추정, 중국은 CAGR 11.0%로 성장 예측

미국의 맨틀세포 림프종 시장은 2024년에 6억 6,870만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 7억 6,980만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.3%와 6.7%로 예측됩니다. 유럽에서는 독일이 CAGR 4.5%로 성장할 것으로 예측됩니다.

세계의 맨틀세포 림프종 시장 - 주요 동향과 촉진요인 정리

맨틀세포 림프종이 암 분야 임상 및 연구에서 주목받는 이유는 무엇인가?

비호지킨림프종 중에서도 희귀하고 공격성이 높은 맨틀세포림프종(MCL)은 복잡한 생물학적 특징, 장기 예후가 좋지 않은 점, 효과적인 치료 전략의 필요성 등으로 인해 전 세계 종양학계의 주목을 받고 있습니다. 전체 비호지킨림프종의 약 6-8%를 차지하는 MCL은 림프절 '맨틀 영역'의 B세포에서 발생하며, t(11;&14) 염색체 전좌에 의한 사이클린 D1의 과발현이 특징입니다. 대부분의 저악성 림프종과 달리 MCL은 공격적인 임상 경과를 보이는 경우가 많으며, 초기 치료 후에도 재발을 반복하며 빠르게 진행됩니다. 이 때문에 MCL은 연구와 치료법 혁신에 있어 우선순위가 높은 질환으로 간주되고 있습니다. 기존의 화학요법이나 줄기세포 이식은 관해의 지속성에 한계가 있기 때문에 임상의와 연구자들은 조기 발견 전략과 표적 치료법 개발에 점점 더 많은 노력을 기울이고 있습니다. 또한, 이 질환의 불균일성과 환자 간 치료 효과의 편차는 맞춤형 의료와 바이오마커 기반 접근법의 중요성을 강조하고 있습니다. 또한, 혈액 전문의의 인식이 높아지고, 진단 도구가 개선되고, 분자 프로파일링에 대한 접근성이 높아짐에 따라 보다 정확한 분류와 적시 개입이 가능해졌습니다. 전 세계 암 부담이 계속 증가하고 정밀 종양학의 접근성이 높아짐에 따라 MCL은 더 나은 치료 패러다임과 장기적인 관리 옵션이 절실히 필요한 질환으로 각광받고 있습니다.

새로운 치료법과 약물의 승인은 MCL의 치료 상황을 어떻게 변화시키고 있는가?

최근 표적 치료제, 면역치료제, 차세대 저분자의 등장으로 MCL의 치료 상황은 크게 변화하고 있습니다. 초기 치료는 R-CHOP, hyper-CVAD와 같은 화학요법 병용요법에 이어 적격 환자에게 자가 줄기세포 이식을 시행하는 경우가 많지만, 새로운 약물의 승인으로 재발성 또는 난치성 환자에게 새로운 치료 옵션이 제공되고 있습니다. 이브루티닙, 아카라브루티닙, 자누브루티닙 등의 브루톤형 티로신 키나아제(BTK) 억제제는 MCL 세포의 생존에 중요한 B세포 수용체 신호전달 경로를 억제하는 능력으로 2차 치료의 중심이 되고 있습니다. 이러한 경구용 치료제는 높은 반응률과 관리 가능한 독성 프로파일을 보이며, 지역 및 학술 환경 모두에서 치료 알고리즘에 변화를 가져오고 있습니다. BTK 억제제 외에도 베네토클락스(venetoclax)와 같은 BCL-2 억제제나 레날리도마이드(lenalidomide)와 같은 면역조절제의 사용은 더 깊고 지속적인 관해에 기여하고 있습니다. 이 분야에서는 CAR-T 세포 치료도 유망한 분야로, 재발성 또는 난치성 MCL에 대한 브렉스카부타딘 오토로이셀의 승인은 맞춤형 면역치료의 큰 이정표가 되었습니다. 시너지 효과를 낼 수 있는 이중특이성항체 및 병용요법에 대한 연구도 진행 중입니다. 임상시험에서 유망한 결과가 계속 나오면서 MCL 치료의 패러다임이 화학요법에 의존하던 방식에서 보다 표적화된 환자 중심의 접근 방식으로 진화하고 있어, 선택의 폭이 제한적이었던 환자들에게 희망이 되고 있습니다.

MCL의 관리에서 진단, 환자 계층화, 임상 모니터링은 어떤 역할을 하는가?

MCL은 침습성이 강하고 임상 경과가 다양하기 때문에 정확하고 적시에 진단하는 것이 중요합니다. 면역 표현형 분류, 세포유전학적 분석 및 분자 프로파일링은 의사가 MCL의 진단을 확정하고 조직학적 검사에서 유사하게 보이는 다른 아형 B세포 림프종과 감별할 수 있는 중요한 도구입니다. 면역조직화학적 검사를 통한 사이클린 D1 과발현 검출과 형광 in situ hybridization(FISH)을 통한 t(11;&14) 전좌의 확인은 여전히 진단의 특징입니다. 진단에 그치지 않고, 맨틀세포 림프종 International Prognostic Index(MIPI)와 같은 예후 예측 도구는 환자를 위험 범주로 분류하고, 치료 결정의 지침이 되며, 전체 생존기간을 예측하는 데 도움이 됩니다. 차세대 시퀀싱과 같은 고감도 기술을 이용한 미세잔존병변(MRD) 모니터링은 임상 증상이 나타나기 전에 치료 효과를 평가하고 재발을 예측하기 위한 수단으로 활용되고 있습니다. PET-CT 검사 등의 영상 진단법은 병기 분류와 치료 효과 평가에 여전히 필수적입니다. 또한, 유전자 프로파일링을 통해 MCL의 돌연변이 상황을 더 깊이 이해할 수 있게 되었고, 특정 치료제에 대한 내성을 예측하는 마커가 밝혀져 맞춤형 치료 전략의 길이 열리고 있습니다. 이러한 진단 및 모니터링 도구가 임상 진료에 도입되면 치료의 정확도가 향상될 뿐만 아니라, 조기 개입과 맞춤형 치료 조정을 통해 환자의 예후도 개선될 수 있습니다. 이러한 정밀 진단으로의 전환은 MCL 환자들이 질병의 적절한 단계에서 가장 효과적인 치료를 받을 수 있도록 하는 데 매우 중요합니다.

세계 맨틀세포 림프종 시장의 성장을 촉진하는 요인은 무엇인가?

세계 맨틀세포 림프종 시장의 성장은 질병에 대한 인식 증가, 혈액 악성 종양 이환율 증가, 표적 치료제의 등장, 의료 서비스 접근성 확대 등 다양한 요인이 복합적으로 작용하여 이루어지고 있습니다. 전 세계 암 발병률의 증가와 진단의 정확성 향상으로 인해 MCL 환자 수가 증가하고 있으며, 특히 고령화 사회에서 이 질환이 많이 발생하는 추세입니다. 바이오제약 기업들이 BTK 억제제, BCL-2 길항제, 세포 치료제 개발에 많은 투자를 하면서 환자들에게 새로운 희망을 가져다주고 있어 의약품의 기술 혁신이 중요한 원동력이 되고 있습니다. FDA와 EMA 등 규제기관은 패스트트랙과 희귀의약품 지정을 통해 획기적인 치료제의 승인 절차를 신속히 진행하여 신약의 시장 진입을 가속화하고 있습니다. 또한, 표적 치료제 및 면역치료제 임상시험의 성공은 기존 기업 및 신생 생명공학 기업들의 투자 및 파이프라인 확장을 촉진하고 있습니다. 또한, 신흥 시장의 임상 인프라 및 암 치료 센터의 확장으로 첨단 치료 및 진단에 대한 접근성이 높아지면서 수요가 더욱 증가하고 있습니다. 정밀의료와 동반진단의 수용 확대는 보다 개인화된 치료 요법을 가능하게 하고, 개별 환자와의 만남의 가치를 높이며, 장기적인 질병 관리를 강화하는 데에도 기여하고 있습니다. 주요 시장에서의 우호적인 상환 정책과 보험 적용 범위 확대는 고가의 치료법에 대한 접근성을 높이고 수익 성장을 촉진하고 있습니다. 이러한 요인들이 결합되어 시장 역학은 역동적이고 빠르게 발전하고 있으며, 광범위한 암 치료 분야에서 중요한 관심 분야가 되고 있습니다.

부문

진단 유형(실험실 검사, 영상 검사, 골수 생검, 기타 진단 유형), 치료(진단, 치료), 최종사용자(병원 및 클리닉, 외래 수술 센터, 기타 최종사용자)

조사 대상 기업 사례

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • Celgene Corporation(BMS)
  • Eli Lilly and Company
  • F.?Hoffmann-La Roche Ltd.
  • Gilead Sciences(Kite Pharma)
  • GlaxoSmithKline plc(GSK)
  • Incyte Corporation
  • Janssen Pharmaceuticals(J&J)
  • Merck & Co., Inc.
  • Novartis AG
  • Nurix Therapeutics Inc.
  • Takeda Pharmaceutical Company Ltd.
  • TG Therapeutics Inc.
  • Verastem Oncology
  • Zebra Biologics(Precision BioSciences)

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.27

Global Mantle Cell Lymphoma Market to Reach US$3.7 Billion by 2030

The global market for Mantle Cell Lymphoma estimated at US$2.5 Billion in the year 2024, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Laboratory Exams Diagnosis, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Imaging Tests Diagnosis segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$668.7 Million While China is Forecast to Grow at 11.0% CAGR

The Mantle Cell Lymphoma market in the U.S. is estimated at US$668.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$769.8 Million by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Mantle Cell Lymphoma Market - Key Trends & Drivers Summarized

Why Is Mantle Cell Lymphoma Garnering Increased Clinical and Research Attention in Oncology?

Mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin’s lymphoma, is drawing increasing attention from the global oncology community due to its complex biology, poor long-term prognosis, and the critical need for effective treatment strategies. Representing approximately 6 to 8 percent of all non-Hodgkin lymphoma cases, MCL arises from B-cells in the “mantle zone” of lymph nodes and is characterized by the overexpression of cyclin D1 due to the t(11;14) chromosomal translocation. Unlike many indolent lymphomas, MCL often follows an aggressive clinical course, progressing rapidly with frequent relapses after initial therapy. This has led to MCL being considered a high-priority condition for research and therapeutic innovation. Clinicians and researchers are increasingly focusing on early detection strategies and the development of targeted therapies, as conventional chemotherapy and stem cell transplants offer limited durability in remission. The disease’s heterogeneity and the variation in treatment response among patients also emphasize the importance of personalized medicine and biomarker-led approaches. Additionally, the growing awareness among hematologists, improved diagnostic tools, and increasing access to molecular profiling are contributing to more accurate classifications and timely interventions. As the global cancer burden continues to rise and precision oncology becomes more accessible, MCL is receiving the spotlight it warrants as a disease that urgently requires better treatment paradigms and long-term management options.

How Are Emerging Therapies and Drug Approvals Transforming the Treatment Landscape for MCL?

Recent years have seen a significant transformation in the treatment landscape for mantle cell lymphoma, largely driven by the emergence of targeted therapies, immunotherapies, and next-generation small molecules. While initial treatment often involves combination chemotherapy regimens such as R-CHOP or hyper-CVAD followed by autologous stem cell transplantation in eligible patients, the approval of novel agents is offering new options for relapsed or refractory cases. Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have become central to second-line treatment due to their ability to interfere with B-cell receptor signaling pathways critical to MCL cell survival. These oral therapies have demonstrated high response rates and manageable toxicity profiles, which has shifted treatment algorithms in both community and academic settings. In addition to BTK inhibitors, the incorporation of BCL-2 inhibitors like venetoclax and the use of immunomodulatory drugs such as lenalidomide are contributing to deeper and more durable remissions. The field is also exploring the promise of CAR-T cell therapy, with brexucabtagene autoleucel receiving approval for relapsed or refractory MCL, marking a major milestone in personalized immunotherapy. Research is ongoing into bispecific antibodies and combination regimens that may provide synergistic benefits. As clinical trials continue to yield promising results, the MCL treatment paradigm is evolving from a reliance on chemotherapy toward a more targeted, patient-centric approach, expanding hope for patients who previously had limited options.

What Role Do Diagnostics, Patient Stratification, and Clinical Monitoring Play in Managing MCL?

Accurate and timely diagnosis is critical in the management of mantle cell lymphoma due to its aggressive nature and variable clinical course. Immunophenotyping, cytogenetic analysis, and molecular profiling are key tools that enable physicians to confirm MCL diagnosis and differentiate it from other subtypes of B-cell lymphomas, which may appear similar under histological examination. The detection of cyclin D1 overexpression through immunohistochemistry or the identification of the t(11;14) translocation via fluorescence in situ hybridization (FISH) remains a diagnostic hallmark. Beyond diagnosis, prognostic tools such as the Mantle Cell Lymphoma International Prognostic Index (MIPI) help stratify patients into risk categories, guiding treatment decisions and predicting overall survival. Minimal residual disease (MRD) monitoring using highly sensitive techniques like next-generation sequencing is increasingly being adopted to assess treatment efficacy and anticipate relapse before clinical symptoms emerge. Imaging modalities such as PET-CT scans remain essential for staging and evaluating treatment response. Furthermore, genetic profiling is allowing for deeper insights into the mutational landscape of MCL, revealing markers that may predict resistance to specific therapies and opening avenues for personalized treatment strategies. As these diagnostic and monitoring tools become more integrated into clinical practice, they are not only improving treatment precision but also enhancing patient outcomes through early intervention and tailored therapy adjustments. This shift toward precision diagnostics is crucial in ensuring that patients with MCL receive the most effective therapies at the right stage of their disease.

What Factors Are Driving Growth in the Global Mantle Cell Lymphoma Market?

The growth in the global mantle cell lymphoma market is driven by a confluence of factors including rising disease awareness, increasing incidence of hematologic malignancies, the emergence of targeted therapies, and expanding healthcare access. The growing burden of cancer globally and improvements in diagnostic accuracy have contributed to a rise in identified MCL cases, particularly in aging populations where the disease is more prevalent. Pharmaceutical innovation is a key driver, as biopharmaceutical companies invest heavily in the development of BTK inhibitors, BCL-2 antagonists, and cellular therapies that offer new hope for patients. Regulatory agencies such as the FDA and EMA are expediting the approval process for breakthrough treatments through fast-track and orphan drug designations, accelerating market entry for novel drugs. The success of targeted therapies and immunotherapies in clinical trials is also encouraging more investment and pipeline expansion from both established players and emerging biotech firms. Additionally, the expansion of clinical infrastructure and cancer care centers in emerging markets is increasing access to advanced treatments and diagnostics, further fueling demand. Growing acceptance of precision medicine and companion diagnostics is also enabling more personalized treatment regimens, increasing the value of each patient encounter and enhancing long-term disease management. Favorable reimbursement policies and expanded insurance coverage in key markets are making high-cost therapies more accessible, thereby driving revenue growth. Together, these factors are creating a dynamic and rapidly evolving market for mantle cell lymphoma treatment, positioning it as a significant focus area in the broader oncology therapeutics sector.

SCOPE OF STUDY:

The report analyzes the Mantle Cell Lymphoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Type (Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy, Other Diagnosis Types); Treatment (Diagnosis Treatment, Therapy Treatment); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • Celgene Corporation (BMS)
  • Eli Lilly and Company
  • F.?Hoffmann-La Roche Ltd.
  • Gilead Sciences (Kite Pharma)
  • GlaxoSmithKline plc (GSK)
  • Incyte Corporation
  • Janssen Pharmaceuticals (J&J)
  • Merck & Co., Inc.
  • Novartis AG
  • Nurix Therapeutics Inc.
  • Takeda Pharmaceutical Company Ltd.
  • TG Therapeutics Inc.
  • Verastem Oncology
  • Zebra Biologics (Precision BioSciences)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mantle Cell Lymphoma - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Rare Hematologic Cancers Throws the Spotlight on Mantle Cell Lymphoma as a High-Unmet-Need Oncology Subtype
    • Increased Use of Molecular Diagnostics and Immunophenotyping Propels Early and Accurate Detection of MCL
    • Here's the Story: Advancements in Targeted Therapies and Precision Medicine Strengthen the Business Case for MCL Drug Development
    • Expansion of BTK Inhibitors and Novel Small Molecules Drives Transformation in MCL Treatment Paradigms
    • Here's How CAR-T and Cell-Based Therapies Are Reshaping Relapsed/Refractory MCL Management Strategies
    • Aging Population and Higher Disease Prevalence Among Older Adults Expand the Addressable Market for Tolerable, Oral Therapies
    • Growth in Real-World Evidence and Biomarker Discovery Supports Personalized Treatment Planning in MCL
    • Here's How Minimal Residual Disease (MRD) Monitoring Is Emerging as a Tool for Evaluating Long-Term Remission and Therapy Response
    • Increased Availability of Orphan Drug Designation and Accelerated Approval Pathways Spurs Innovation in MCL Therapeutics
    • Here's How Combination Therapy Strategies Are Improving Progression-Free Survival While Managing Drug Resistance
    • Rising Demand for Outpatient and Home-Based Oncology Care Drives Development of Oral and Subcutaneous Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mantle Cell Lymphoma Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Laboratory Exams Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Laboratory Exams Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Laboratory Exams Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Imaging Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Imaging Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Imaging Tests Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Bone Marrow Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Bone Marrow Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Bone Marrow Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Diagnosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Mantle Cell Lymphoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Mantle Cell Lymphoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Mantle Cell Lymphoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Mantle Cell Lymphoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제